Studieoverzicht

 
 
 
  2022-01 DIRECT-2       Active, not recruiting       Neoadjuvant       HER2- HR+       Both pre- and postmenopausal  
  2021-04 TROPION-Breast01       Active, not recruiting       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal  
  2021-03 EMBER-3       Active, not recruiting       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal  
  2021-02 ZEST       Active, not recruiting       Adjuvant       HER2-, any HR       Both pre- and postmenopausal  
  2020-02 AMEERA-5       Active, not recruiting       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal  
  2020-01 DESTINY-Breast 06       Active, not recruiting       Advanced/metastatic       Any HER2, HR+       Both pre- and postmenopausal  
  2019-01 TIBET       Active, not recruiting       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal  
  2017-03 SONIA       Active, not recruiting       Advanced/metastatic       HER2- HR+       Not applicable  
  2013-01 TRIPLE-B       Active, not recruiting       Advanced/metastatic       TNBC       Both pre- and postmenopausal